Cargando…

Age, Initial Central Retinal Thickness, and OCT Biomarkers Have an Influence on the Outcome of Diabetic Macular Edema Treated With Ranibizumab– Tri-center 12-Month Treat-and-Extend Study

Objective: We report the tri-center 1-year outcomes of a treat-and-extend (T&E) regimen in four-week intervals with ranibizumab for diabetic macular edema (DME). Methods: In this retrospective study, all eyes received 3 monthly loading injections of 0.5 mg ranibizumab, followed by a T&E regi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Chun-Ting, Hsieh, Yi-Ting, Lin, Chun-Ju, Wang, Jia-Kang, Lin, Chih-Ying, Hsia, Ning-Yi, Bair, Henry, Chen, Huan-Sheng, Chiu, Chiung-Yi, Weng, Shao-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8126636/ https://www.ncbi.nlm.nih.gov/pubmed/34012972 http://dx.doi.org/10.3389/fmed.2021.668107

Ejemplares similares

Comparison of Choroidal Thickness, Foveal Avascular Zone, and Macular Capillary Density in Macular Edema Secondary to Branch Retinal Vein Occlusion Treated with Ranibizumab or Aflibercept—A Prospective Study
por: Huang, Yu-Te, et al.
Publicado: (2022)

Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital
por: Ku, Wei-Ning, et al.
Publicado: (2022)

Treat-and-Extend vs. Pro Re Nata Regimen of Ranibizumab for Diabetic Macular Edema—A Two-Year Matched Comparative Study
por: Lai, Tso-Ting, et al.
Publicado: (2022)

Comparison of the Effect of Ranibizumab and Aflibercept on Changes in Macular Choroidal Thickness in Patients Treated for Diabetic Macular Edema
por: Sarda, Valérie, et al.
Publicado: (2020)

Short-Term Outcomes of Refractory Diabetic Macular Edema Switch From Ranibizumab to Dexamethasone Implant and the Influential Factors: A Retrospective Real World Experience
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
por: Kim, Moosang, et al.
Publicado: (2013)

Systemic Associations with Residual Subretinal Fluid after Ranibizumab in Diabetic Macular Edema
por: Tsai, Meng-Ju, et al.
Publicado: (2017)

Combined intravitreal ranibizumab and posterior subtenon triamcinolone acetonide injections for patients with diabetic macular edema refractory to intravitreal ranibizumab monotherapy
por: Chiu, Chiung-Yi, et al.
Publicado: (2021)

Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema
por: Lai, Ivan Pochou, et al.
Publicado: (2020)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections
por: Chang, Yen-Chieh, et al.
Publicado: (2023)

Intravitreal aflibercept combined with transpupillary thermotherapy in the treatment of refractory macular edema due to primary uveal melanoma
por: Huang, Yu-Te, et al.
Publicado: (2022)

Intravitreal Aflibercept as a Rescue Therapy for Retinal Neovascularization and Macular Edema due to Eales Disease
por: Hsia, Ning-Yi, et al.
Publicado: (2021)

A Novel Machine Learning Algorithm to Automatically Predict Visual Outcomes in Intravitreal Ranibizumab-Treated Patients with Diabetic Macular Edema
por: Chen, Shao-Chun, et al.
Publicado: (2018)

Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab
por: Hu, Yuxiang, et al.
Publicado: (2019)

Clinical effects and safety of treating diabetic macular edema with intravitreal injection of ranibizumab combined with retinal photocoagulation
por: Yan, Panshi, et al.
Publicado: (2016)

Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema
por: Shiraya, Tomoyasu, et al.
Publicado: (2017)

Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema After Dexamethasone Implants
por: Huang, Yu-Te, et al.
Publicado: (2022)

Secondary Full-thickness Macular Holes after Diabetic Vitrectomy: Clinical Manifestations and Rational Approaches to the Treatment
por: Hsia, Yun, et al.
Publicado: (2022)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)

Comparing Macular Thickness Measurements in Patients with Diabetic Macular Edema with the Optos Spectral OCT/SLO and Heidelberg Spectralis HRA + OCT
por: Sachdev, Amun, et al.
Publicado: (2016)

Comparison of Intravitreal Dexamethasone Implant and Ranibizumab in Vitrectomized Eyes with Diabetic Macular Edema
por: Wang, Jia-Kang, et al.
Publicado: (2021)

Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
por: Best, Anne-Laurence, et al.
Publicado: (2018)

Real-World Outcomes in Patients with Diabetic Macular Edema Treated Long Term with Ranibizumab (VISION Study)
por: Van Aken, Elisabeth, et al.
Publicado: (2020)

Comparison of Innovator vs. Biosimilar Ranibizumab in Treating Diabetic Macular Edema: A Multicenter Retrospective Study
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

OCT-Angiography Changes in Patients with Diabetic Macular Edema Treated with Intravitreal Dexamethasone Implant
por: Carnota-Méndez, Pablo, et al.
Publicado: (2022)

Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases
por: Chen, Yen-Po, et al.
Publicado: (2019)

Full thickness macular hole following intravitreal ranibizumab injection for diabetic macular edema; a rare complication or coincidence?
por: Arifoglu, Hasan Basri, et al.
Publicado: (2015)

Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013)

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study
por: Prünte, Christian, et al.
Publicado: (2016)

Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
por: Kourlaba, Georgia, et al.
Publicado: (2016)

Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study)
por: Gascon, Pierre, et al.
Publicado: (2021)

Retinal Thickness Deviation: A New OCT Parameter for Assessing Diabetic Macular Edema
por: Marolo, Paola, et al.
Publicado: (2023)

Full-thickness macular hole formation in proliferative diabetic retinopathy
por: Tsui, Mei-Chi, et al.
Publicado: (2021)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Anatomical and functional responses in eyes with diabetic macular edema treated with “1 + PRN” ranibizumab: one-year outcomes in population of mainland China
por: Lai, Kunbei, et al.
Publicado: (2020)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Multifocal electroretinography changes at the 1-year follow-up in a cohort of diabetic macular edema patients treated with ranibizumab
por: Baget-Bernaldiz, Marc, et al.
Publicado: (2017)

Aflibercept versus ranibizumab for treating persistent diabetic macular oedema
por: ROA Vandekerckhove, Kristof
Publicado: (2015)

Intravitreal Ranibizumab Versus Intravitreal Ranibizumab Combined with Posterior Subtenon Triamcinolone Acetonide in Diabetic Macular Edema
por: Karatas, Gamze, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q1fo5sith76qjcrdfhhotadcbp